Company Description
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally.
The company offers robotic magnetic navigation (RMN) systems, such as the Genesis RMN, which enable physicians to complete interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites; and GenesisX RMN, which is designed to enhance the accessibility of RMN by eliminating the lengthy construction cycle necessary to install prior generation RMN systems.
It also offers Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and x-ray systems.
In addition, the company offers disposables and other accessories, including QuikCAS, an automated catheter advancement single-use disposable device; iCONNECT; V-CAS; and MAGiC catheter for cardiac ablation procedures.
Further, it provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components.
It markets its products through direct sales force, distributors, and sales agents. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri.
| Country | United States |
| Founded | 1990 |
| IPO Date | Aug 12, 2004 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 139 |
| CEO | David Fischel |
Contact Details
Address: 710 North Tucker Boulevard, Suite 110 Saint Louis, Missouri 63101 United States | |
| Phone | 314 678 6100 |
| Website | stereotaxis.com |
Stock Details
| Ticker Symbol | STXS |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001289340 |
| CUSIP Number | 85916J409 |
| ISIN Number | US85916J4094 |
| Employer ID | 94-3120386 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Dr. David Leo Fischel C.A.I.A., C.F.A., C.P.A., M.B.A. | Chief Executive Officer and Chairman |
| Keith Galloway | Vice President of Operations |
| Patricia S. Williams Esq. | General Counsel and Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 4, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 4, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 14, 2025 | 10-K | Annual Report |
| Mar 3, 2025 | 8-K | Current Report |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Sep 11, 2024 | EFFECT | Notice of Effectiveness |
| Sep 6, 2024 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Sep 6, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Aug 30, 2024 | UPLOAD | Filing |